Brian Barnett

Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries

Abstract Objective: This retrospective study compared the real-world incidence and costs of systemic treatment-related adverse events (AEs) in patients with metastatic breast cancer in a Medicaid population. Methods: Insurance claims data for adult women who received biologic or chemotherapy (± hormonal therapy) for metastatic breast cancer between 2006–2013 were extracted from the Truven Health MarketScan® Multi-State Medicaid database. Incidence of AEs (per 100 person years) and average monthly AE-related healthcare costs (per-patient-per-month) during each line of therapy (first or later lines) were estimated. The association between AEs and total all-cause healthcare costs was estimated using multivariable regression. Results: A total of 729 metastatic breast cancer patients were analyzed. Hematological (202.3 per 100 person years) and constitutional AEs (289.6 per 100 person years) were the most common class of AEs reported. Unadjusted per-patient-per-month AE-related expenditure by class were highest for hematological AEs (

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

1524), followed by gastrointestinal (

Abstract P1-16-04: First-line chemotherapy for breast cancer patients by site of care (SOC): Treatment patterns, cost and quality indicators

839) and constitutional AEs (

Abstract P4-14-03: What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine?

795), with anemia (

Abstract P4-14-04: A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond

942), nausea/vomiting (

Abstract P5-21-03: Delay in trastuzumab initiation leads to decreased overall survival in patients with HER2+ early stage breast cancer

699), and leukopenia/neutropenia (

Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice

550) having incurred the highest total AE-related costs. Adjusted total all-cause monthly costs increased with the number of AEs (

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.

19,701 for >7 AEs,

Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.

16,264 for 4 − 6 AEs, and

Adverse event-related costs for breast cancer treatment among Medicaid patients.

13,731 for 1 − 3 AEs) compared to no AEs (